http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022050113-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b603ecd95b3b1497ae9f30752a676c0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6afbd19f560437f5d406b637c676c322 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-347 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-689 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20 |
| filingDate | 2019-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f23ce54e0c7863f658f060cfe9f29df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b86ec52dd8828fc76b99eaf06e9461a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44300d90fbc98407e80996671c068f18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdda4f94394d3701b4eabf2879acb6f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c53fab74a07350251683da4ff4dff1e |
| publicationDate | 2022-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022050113-A1 |
| titleOfInvention | Use of amniotic fluid peptides for predicting postnatal renal function in congenital anomalies of the kidney and the urinary tract |
| abstract | Bilateral congenital anomalies of the kidney and urinary tract (CAKUT) are the main cause of childhood chronic kidney disease (CKD). Accurate and non-biased prenatal prediction of postnatal disease evolution is currently lacking, but is essential for prenatal counseling and disease management. Here the inventors aimed to develop an objective and quantifiable risk prediction method based on amniotic fluid (AF) peptides. 178 fetuses with bilateral CAKUT were included in a prospective multicenter study. The AF peptide content was studied using capillary electrophoresis coupled to mass spectrometry. The endpoint was early-onset renal failure (CKD stage 3-5) or death due to end-stage renal disease at two years of age. Among the ˜7000 peptide candidates, 98 were associated with early severe renal failure. The most frequently found peptides associated with severe disease were fragments from extracellular matrix proteins and thymosin-P4. Combination of those 98 peptides in a classifier lead to the prediction of postnatal renal outcome in a blinded validation set of 51 patients with a 88% (95% CI: 64-98) sensitivity, 97% (95% CI: 85-100) specificity and an AUC of 0.96 (95% CI: 0.87-1.00), outperforming predictions based on currently used clinical methods. The classifier also predicted normal postnatal renal function in 75% of terminated pregnancies where fetopathology showed kidneys compatible with normal life. Analysis of AF peptides thus allows a precise and quantifiable prediction of postnatal renal function in bilateral CAKUT with potential major impact on pre- and postnatal disease management. |
| priorityDate | 2018-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 225.